t wasn’t your usual earnings call.

Dr. Patrick Soon-Shiong opened a routine report on his company NantHealth’s first quarter results with this: “Before I go into the details about our business, I would like to take this opportunity to get something off my chest.”

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • there she blows again – Rebecca the Harvard grad with an axe to grind. if you really want to cover Soon Shiong, why not cover ALL the news, including FDA approvals for the combination immunotherapy protocols that will be informed by GPS Cancer? oh, that’s right Rebecca doesn’t do reporting, only bashing. Soon Shiong is bent on saving lives, and RR is bent on slowing him down so big pharma can catch up. got to protect that swamp, right RR?

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.